Vincristine and prednisone for the induction of remissions in acute childhood leukaemia.
A total of 65 children with acute lymphoblastic leukaemia and seven with other types of acute leukaemia received treatment with a combination of vincristine and prednisone. In all 122 courses of treatment were given. Of 22 patients with acute lymphoblastic leukaemia who received this as their first treatment, all achieved complete remission. The complete remission rates were 82% for patients with acute lymphoblastic leukaemia in their first relapse, 63% in the second relapse, and much lower in subsequent relapses and in the patients with other types of acute leukaemia. Alopecia and gastrointestinal and neuromuscular toxicity occurred respectively in 51%, 29%, and 21% of instances, only the last of these side-effects of vincristine being dose-related. Most of the complete remissions were obtained with a total dose of vincristine which carried only a low risk of neurotoxicity.
D000208:Acute Disease; D000505:Alopecia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D004357:Drug Synergism; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D009135:Muscular Diseases / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D011241:Prednisone / Q000008:administration & dosage*; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects
D014750:Vincristine; D011241:Prednisone